United Kingdom · Medical Intelligence beta
Track the changes that matter without turning every update into a medical claim.
GreenGuruAI is productising the source-checking work behind our UK patient guidance. The beta separates medical-cannabis access, patient rights, providers, medicines and adjacent cannabis regulation so organisations can see what changed, which source supports it and what should be reviewed next.
Exploring CSC regulation in Spain? Visit the Spain CSC Signal pilot →
Initial coverage
Four streams, kept deliberately separate.
Medicines and prescribing
MHRA, NICE, NHS and GOV.UK material that changes the medical-cannabis or controlled-medicine context.
Patient rights and practical rules
Driving, workplace, carrying, travel and other material government or regulator guidance.
Clinic and pharmacy landscape
Provider openings, closures, ownership or material service changes, checked against primary provider and regulator evidence.
Medicine and price intelligence
Material product, fee and availability changes where the source can be verified and the boundary between price, stock and clinical advice remains clear.
Reviewed UK feed
Current published Signals.
ACMD medical-cannabis review concluding — report expected by end of 2026
What changed: The Advisory Council on the Misuse of Drugs says its Cannabis Based Products for Medicinal Use working group is concluding its report and expects publication by the end of 2026. This is a timetable update, not a change to current UK medical-cannabis law, prescribing eligibility or patient rights.
Why it matters: The forthcoming ACMD report could recommend changes affecting the post-2018 CBPM framework. Until the report and any subsequent government response are published, GreenGuru should not imply that the review has already changed law or policy.
Medical-cannabis patients · Prescribers and clinics · Pharmacies and compliance teams · Cannabis-sector analysts
United Kingdom, United Kingdom
Developing evidence
Evidence: Advisory Council on the Misuse of Drugs / GOV.UK
Open original source ↗
Reviewed:
View change history
Previous GreenGuru position: UK CBPM rules remain unchanged by this work-programme update.
Reviewed GreenGuru action: Add to UK Watch as an official review-timeline development. Use wording 'ACMD review concluding — report expected by end of 2026' where GreenGuru discusses the review timetable.
FSA recommendation stage — ministerial authorisation pending
What changed: The Food Standards Agency has made recommendations to ministers concerning the first three high-purity CBD novel-food applications to reach this stage of the UK authorisation process. Ministerial authorisation remains pending; the products must not be described as authorised on the basis of the FSA recommendation.
Why it matters: This is a material CBD food-regulation development, but it is separate from the UK's medical-cannabis prescribing framework. The FSA recommendation is not itself product authorisation. Subsequent EU scientific assessment is relevant regulatory context but does not change the current UK authorisation status.
CBD and consumer-product businesses · Food regulatory and compliance teams · Cannabis-sector analysts
England, Wales and Northern Ireland, United Kingdom
Official primary source
Evidence: Food Standards Agency / GOV.UK
Open original source ↗
Reviewed:
View change history
Previous GreenGuru position: CBD novel foods follow the food-authorisation framework, separately from prescription medical cannabis.
Reviewed GreenGuru action: Keep the Signal status 'FSA recommendation stage — ministerial authorisation pending'. Record the subsequent EFSA scientific opinion as EU/SPS context without describing it as EU market authorisation or as a change to UK medical-cannabis law.
Feed checked: 2026-09-24. CBD/consumer-product regulation is explicitly separated from prescription medical-cannabis access where the underlying framework differs.
What the pilot tests
Would organisations pay to have reviewed change routed to them instead of monitoring every source themselves?
- source-linked alerts for material changes;
- clear jurisdiction/topic classification and review date;
- change history rather than silent page edits;
- later: organisation watchlists, widgets and API access if the pilot validates demand.
We are deliberately not offering prescribing recommendations, dose suggestions or automated clinical decisions.
Founding pilot
Tell us what your organisation currently monitors by hand.
Initial conversations are aimed at clinics, patient organisations, pharmacies, legal/regulatory professionals and other teams supporting medical-cannabis patients.
Bring one public source or recurring question your team monitors. We will walk through a reviewed Signal against that example so you can assess the source trail, change history and review prompts, then tell us what would make the workflow useful to your team.
Please do not submit patient, member or other confidential personal data. The interest form starts a conversation; pilot scope, timing and commercial terms will be agreed directly before participation begins.
GreenGuruAI provides independent information and intelligence. It is not a clinic, prescriber, pharmacy, regulator or substitute for qualified medical or legal advice.